Imugene appoints leading cancer researcher to board

Company News

by Anna Napoli

Biotech company, Imugene (ASX:IMU) has today announced the appointment of a leading cancer researcher to its Scientific Advisory Board.

The company says Professor Pravin Kaumaya of Ohio State University's Comprehensive Cancer Centre is a leader in cancer vaccine research and will advance Imugene's cancer immune-therapy product pipeline.

The professor is the lead inventor of Imugene's newly licensed peptide cancer vaccine programs.

Imugene also announced the retirement of Chief Scientific Officer Professor Ursula Wiedernann.

Shares in Imugene (ASX:IMU) are trading flat at $0.02.